Wall Street has been buying AbbVie, Allergan, and Pfizer and short-sellers have stayed away from these stocks. Here's why.
Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.
Corporate tax inversion is becoming endemic in the health care industry. Where do you stand after viewing both the positive and negative implications of this tax-fleeing corporate strategy?
World Cup fever spreads to dividend stock AbbVie
AbbVie and Shire. Valeant and Allergan. The drugmaker deal dances are underway -- but it takes two to tango.
A positive result at an FDA advisory committee for AstraZeneca's olaparib, which will compete with AbbVie's veliparib, could make the British company more attractive to Pfizer.
Investors can learn something from Medivation, GlaxoSmithKline, Amarin and AstraZeneca.
Yes, Pfizer should buy Bristol-Myers Squibb instead of AstraZeneca, but it won't.
It'd be pretty difficult to unseat Bank of America's purchase of Countrywide Financial, but this nearly $4 billion biotech buyout may go down as one of the worst deals on record.
From cancelled contracts to hostile takeovers, these three companies ended at the bottom of the stock market today